Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adeno-associated virus-mediated gene delivery.

R O Snyder1

  • 1Division of Molecular Medicine, Children's Hospital, Boston, USA. rsnyder@hihg.med.harvard.edu

The Journal of Gene Medicine
|March 30, 2000
PubMed
Summary

Recombinant adeno-associated viral (rAAV) vectors show promise for safe and effective gene therapy, offering long-term protein expression and genetic disease correction after one dose. Research focuses on enhancing rAAV vector performance, manufacturing, and safety data.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishment of two quantitative nested qPCR assays targeting the human EPO transgene.

Gene therapy·2016
Same author

Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping.

Gene therapy·2011
Same author

Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity.

Gene therapy·2004
Same author

AAV and RT-PCR: true or false?

Molecular therapy : the journal of the American Society of Gene Therapy·2000
Same author

Gene delivery to in situ veins: differential effects of adenovirus and adeno-associated viral vectors.

Journal of vascular surgery·2000
Same author

Selective uptake and sustained expression of AAV vectors following subcutaneous delivery.

The journal of gene medicine·2000

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Gene Therapy

Background:

  • Gene therapy aims to treat genetic diseases by delivering therapeutic genes.
  • Various viral vectors are under development for gene delivery, each with specific applications.
  • Recombinant adeno-associated viral (rAAV) vectors are emerging as a leading platform for gene therapy.

Purpose of the Study:

  • To highlight the safety and efficacy of rAAV vectors for long-term gene expression.
  • To discuss the versatility of rAAV vectors across different human diseases and tissues.
  • To identify key areas of ongoing research for improving rAAV vector technology.

Main Methods:

  • Review of current research on rAAV vector development.
  • Analysis of safety and efficacy data from preclinical and clinical studies.

Related Experiment Videos

  • Exploration of manufacturing and performance enhancement strategies for rAAV vectors.

    • Main Results:

    • rAAV vectors demonstrate safety and efficacy for sustained protein expression and genetic disease correction.
    • Single administration of rAAV vectors can lead to long-term therapeutic effects.
    • rAAV vectors are versatile, targeting a growing range of tissues and diseases.

    Conclusions:

    • rAAV vectors are a promising tool for somatic gene therapy.
    • Continued research in manufacturing and data accumulation is crucial for clinical translation.
    • The versatility and efficacy of rAAV vectors support their broad application in treating genetic disorders.